AZTR News & Events

Azitra added The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04. ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor-associated rash. The multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 clinical study is designed to evaluate the safety and tolerability of topical ATR04-484 for the treatment of EGFRi-associated dermal toxicity affecting the face of adult patients. The key objectives of the study will be to assess the safety and tolerability of topical ATR04-484 and to evaluate early efficacy signals. The study is currently enrolling patients for Cohort 1, which is anticipated to enroll a total of eight patients.

Azitra announced it received a notice from the staff of NYSE American approving Azitra's plan to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. Azitra must regain compliance with the continued listing standards by April 1, 2027. If Azitra is not in compliance with the continued listing standards by April 1, 2027, or if Azitra does not make progress consistent with the Plan during the plan period, NYSE Regulation staff will initiate delisting proceedings as appropriate.

Azitra files to sell 38.9M shares of common stock for holders

Maxim Group LLC is acting as the sole placement agent in connection with the Offering.